What are the risks of drug-eluting stents? Drug-eluting stents (DES) have dramatically improved the treatment of coronary artery disease by significantly reducing the risk of in-stent restenosis (re-narrowing of the artery). However, they are not without risks, primarily related to the presence of the drug and its polymer coating.
The most significant and serious risk of a DES is stent thrombosis, which is the formation of a blood clot inside the stent. This can lead to a heart attack or even death. While the risk is low, it is a critical concern that is carefully managed by cardiologists.
Here are the key risks associated with drug-eluting stents:
1. Stent Thrombosis (Blood Clots)
Delayed Healing: The anti-proliferative drug on a DES prevents the excessive growth of scar tissue, but it also slows down the natural healing process of the artery. It can delay the growth of a new, healthy cell layer (endothelium) over the stent struts. This leaves the metal and polymer exposed to the bloodstream for a longer period, making the stent a potential site for a blood clot to form.
Dual Antiplatelet Therapy (DAPT): To mitigate this risk, patients with a DES must take a combination of antiplatelet medications—typically aspirin and a second drug like clopidogrel (Plavix), prasugrel, or ticagrelor. This "dual antiplatelet therapy" prevents platelets from sticking together and forming a clot.
Risk of Premature Discontinuation: The most significant risk factor for stent thrombosis is the premature discontinuation of DAPT. If a patient stops taking these medications too soon, the risk of a life-threatening clot increases sharply. For this reason, cardiologists carefully consider whether a patient is likely to be compliant with the medication regimen for a prolonged period.
2. Side Effects of Dual Antiplatelet Therapy (DAPT)
While DAPT is essential for preventing thrombosis, it comes with its own set of risks.
Increased Bleeding Risk: The primary side effect of antiplatelet medication is an increased risk of bleeding. This can range from easy bruising and nosebleeds to more serious internal bleeding, such as in the gastrointestinal tract.
Impact on Other Procedures: The need for prolonged DAPT can complicate other surgeries or medical procedures. Patients may need to carefully time non-cardiac surgeries or temporarily stop their medication under a doctor's supervision, which can increase the risk of a cardiac event.
3. Allergic or Inflammatory Reactions
In some rare cases, the polymer coating or the drug itself can cause a hypersensitivity or inflammatory reaction in the artery. This can lead to chronic inflammation and delayed healing, which may contribute to very late stent thrombosis (clot formation more than a year after the procedure).
4. Very Late Stent Restenosis
While DES were designed to prevent restenosis, in some rare cases, re-narrowing can still occur, particularly with older generations of stents. This can be due to various factors, including an exaggerated inflammatory response to the stent.
It's important to note that advances in stent technology have significantly reduced these risks over time. Newer generations of DES use more biocompatible polymers, thinner struts, and more effective drugs, leading to faster healing and lower rates of stent thrombosis than the first-generation stents. Today, a DES is considered a safe and highly effective treatment for most people with coronary artery disease when used as prescribed and with proper medical follow-up.